Ilika validates Goliath battery breakthrough, Stereax customer delivery expectations

Ilika PLC reported significant progress across its Stereax and Goliath battery programs, with CEO Graeme Purdy anticipating revenue recognition from Stereax customer deliveries by year-end 2025 following successful trial production and alpha sample validation. Concurrently, the company validated its Goliath P1 prototypes for safety, is testing P1.5 models (five times capacity), and expects to advance to 50Ah P2 prototypes later this year. This development is supported by a £1.25 million UK government grant and strategic allocation of recent capital raise funds, signaling key technical milestones and a clear path towards commercialization.

Analysis

Ilika PLC has reported significant operational progress, positioning the company for a pivotal transition towards commercialization in 2025. The primary catalyst is the Stereax battery program, where the installation of manufacturing equipment at partner Cirtec Medical's facility has enabled encouraging trial production. CEO Graeme Purdy's guidance for recognizing revenue from customer deliveries within the current calendar year hinges on the successful validation of alpha sample cells, a key milestone expected before year-end. Concurrently, the Goliath program has achieved a critical technical de-risking milestone through the safety validation of its P1 prototype, which demonstrated inert behavior in nail penetration tests, a notable advantage over standard lithium-ion cells. The company is actively scaling this technology, testing P1.5 prototypes with five times the capacity and planning for 50Ah P2 prototypes later in the year. This dual-track development is financially supported by a recent capital raise, strategically allocated with two-thirds funding Goliath development, and a £1.25 million non-dilutive grant from the UK government, with prospects for further grant funding to mitigate future equity dilution.

Key Decisions for Investors

• Investors should monitor for the announcement of validated Stereax alpha cells, as this is the final technical hurdle before Ilika can begin customer deliveries and transition to a revenue-generating company this year.
• The demonstrated safety performance of the Goliath prototype is a key long-term differentiator; however, investors should weigh this potential against the execution risk and capital required to scale production to the 50Ah P2 prototype stage.
• Given the company's reliance on grants and capital raises, it is prudent to assess the current cash runway relative to the development timelines for both the near-term Stereax commercialization and the more capital-intensive Goliath pilot line.